version of the Guidelines, which is freely available via the ESC and EAS websites and
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …

Antibody therapeutics are a large and rapidly expanding drug class providing major health
benefits. We provide a snapshot of current antibody therapeutics including their formats …

Antibodies are the most rapidly growing drug class and have a major impact on human
health, particularly in oncology, autoimmunity and chronic inflammatory diseases. Many of …

Background Bococizumab is a humanized monoclonal antibody that inhibits proprotein
convertase subtilisin–kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein …

Abstract for the 2017 Focused Update to the 2016 Expert Consensus Decision Pathway In
2016, the American College of Cardiology published the first expert consensus decision …

The gene encoding PCSK9 was first identified and linked to the phenotype of familial
hypercholesterolaemia approximately 15 years ago. Soon after, studies uncovered the role …

Drug development in cardiovascular disease is stagnating, with lack of efficacy and adverse
effects being barriers to innovation. Human genetics can provide compelling evidence of …

Variants in proprotein convertase subtilisin/kexin type 9 (PCSK9) provide insights into
mechanisms regulating low-density lipoprotein (LDL) levels. Human monoclonal antibodies …

Unknown 15 years ago, PCSK9 (proprotein convertase subtilisin/kexin type 9) is now
common parlance among scientists and clinicians interested in prevention and treatment of …

The first randomized controlled data from cardiovascular outcomes trials with proprotein
convertase subtilisin/kexin type 9 (PCSK9) inhibitors have now been reported. 1, 2 This …